Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.

We provide access to a range of journals, databases and other evidence-based resources for health and social care staff in England. You'll need an NHS OpenAthens account to access most of these ...